CHERYL ARD: Open Payments
NPI 1780938647 · STATESBORO, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$386 in 20 payments from 9 companies in 2025. Trend: 2023 $654 · 2024 $508 · 2025 $386
Food & beverage: $386
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $205 |
| Novo Nordisk Inc | 3 | $62 |
| PFIZER INC. | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Abbott Laboratories | 1 | $19 |
| Amgen Inc. | 1 | $18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| GlaxoSmithKline, LLC. | 1 | $14 |
Products named: VRAYLAR, QULIPTA, Wegovy, UBRELVY, PREVNAR 20, MOUNJARO, FREESTYLE LIBRE 3, OTEZLA.
Industry payments across GA — which companies pay providers there.
